International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
Shuji Isaji, Shugo Mizuno, John A Windsor...
https://pubmed.ncbi.nlm.nih.gov/29191513/Actively Recruiting
Led by University Hospital, Ghent · Updated on 2025-04-02
45
Participants Needed
8
Research Sites
104 weeks
Total Duration
This research aims to improve prediction of surgery success for patients with borderline resectable BR and locally advanced pancreatic ductal adenocarcinoma LAPDA undergoing neoadjuvant chemotherapy with FOLFIRINOX. The study focuses on combining diffusion-weighted magnetic resonance imaging DW-MRI, radiomics, and multi-omics profiling of blood samples to better identify which tumors can be surgically removed. This approach seeks to reduce unnecessary surgeries and improve treatment decisions due to challenges in current imaging and tumor marker accuracy. Participants will receive standard care including CT scans, CA 19-9 blood tests, and FOLFIRINOX chemotherapy. Additional DW-MRI scans and blood samples for genetic and molecular analysis will be collected before and after chemotherapy. If imaging shows no tumor progression and CA 19-9 levels decrease, surgical exploration may be pursued. Blood samples will also be taken during surgery and at the first follow-up visit to further evaluate tumor characteristics and treatment response. Throughout the study, participants will undergo imaging tests, blood draws, and questionnaires about health status and quality of life. Researchers will analyze data to predict surgical resectability, assess complications, and evaluate disease-free and overall survival over several years. This comprehensive monitoring aims to enhance personalized treatment plans while minimizing risks from unnecessary procedures.
CONDITIONS
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Ghent
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration as per standard chemotherapy protocol
Participants receive neoadjuvant treatment with FOLFIRINOX to reduce tumor size and improve surgical outcomes.
Visits according to chemotherapy schedule (not specified)
Duration - Before and after chemotherapy period
Participants undergo imaging with CT scan and two additional DW-MRI scans, along with peripheral blood sampling for multi-omics profiling to assess tumor response and predict surgical resectability after chemotherapy.
At least 2 imaging visits and multiple blood sample collections (timing before and after chemotherapy)
Duration - 1 surgical procedure and immediate post-operative period
Participants with no tumor progression and decreased CA 19-9 levels after chemotherapy are considered for surgical exploration to assess resectability and possibly proceed with tumor resection.
1 visit for surgery and intraoperative blood samples
Duration - Up to several weeks post-surgery (exact duration not specified)
Participants have a post-operative consultation where blood samples are collected for further analysis, and ongoing monitoring of recovery and outcomes occurs.
1 post-operative consultation visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Shuji Isaji, Shugo Mizuno, John A Windsor...
https://pubmed.ncbi.nlm.nih.gov/29191513/Giovanni Marchegiani, Valentina Todaro, Enrico Boninsegna...
https://pubmed.ncbi.nlm.nih.gov/29679211/Luís Filipe Abreu de Carvalho, Filip Gryspeerdt, Wim Ceelen...
https://pubmed.ncbi.nlm.nih.gov/40361171/Georgios Gemenetzis, Vincent P Groot, Jun Yu...
https://pubmed.ncbi.nlm.nih.gov/30080739/Ramdane A Harouaka, Merisa Nisic, Si-Yang Zheng
https://pubmed.ncbi.nlm.nih.gov/23832928/Elodie Sollier, Derek E Go, James Che...
https://pubmed.ncbi.nlm.nih.gov/24061411/Vladimir Bobek, Robert Gurlich, Petra Eliasova...
https://pubmed.ncbi.nlm.nih.gov/25493031/Luís Filipe Abreu de Carvalho, Wim Ceelen, Annick Meertens...
https://pubmed.ncbi.nlm.nih.gov/42384236/Katherine E Poruk, Vicente Valero, Tyler Saunders...
https://pubmed.ncbi.nlm.nih.gov/26756760/Lei Tang, Xiaohong Joe Zhou
https://pubmed.ncbi.nlm.nih.gov/30311988/University Hospital, Ghent
Lead Sponsor